TORONTO, June 03, 2025 (GLOBE NEWSWIRE) — Guardian Capital LP ( “Guardian Capital“) is excited to announce the launch of GuardBonds(TM) 2028 Investment Grade Bond Fund (Cboe: GBFE) and GuardBonds(TM) 2029 Investment Grade Bond Fund (Cboe: GBFF) (the “New GuardBonds(TM) Funds) to join the existing suite of GuardBonds(TM) funds which includes GuardBonds(TM) 2025 Investment Grade […]

(NASDAQ:AKRO), SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at

SUNRISE, Fla., June 03, 2025 (GLOBE NEWSWIRE) — Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an exclusive license agreement with Suzhou Intragrand Pharma Co., Ltd for ITG-1052, an investigational PDE4 inhibitor. ITG-1052 represents the addition of a

(NASDAQ:BCRX), RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as

(NasdaqGM:SION), WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in

(LSE:OXB), Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will advise OXB on

(NasdaqGM:VEON), Islamabad and Dubai, June 3, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or “the Company”), announces that it has successfully closed the partnership for the pooling and management of telecommunications infrastructure assets in Pakistan with Engro Corporation Limited (“Engro Corp”). VEON's infrastructure assets housed under Deodar (Private) Limited have now vested

VICTORIA, Seychelles, June 03, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has officially launched the second year of its Anti-Scam Month, a global initiative run to spread crypto security awareness. In a world where scams have become as sophisticated as the technologies meant to prevent them, Bitget is taking a

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire June 03, 2025 RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst

Graphite One becomes the first Alaskan Critical Mineral mining project on the FAST-41 Dashboard FAST-41 status follows completion of Graphite One Feasibility Study funded by a $37.3M award under the Defense Production Act G1 enters Permitting Phase as Presidential Critical Mineral Executive Order calls for “Immediate Measures to Increase American Mineral Production” and “Unleashing Alaska's